Open AccessKnowing When to Use Stereotactic Ablative Radiation Therapy in Oligometastatic Cancer
Author(s) -
Davide Franceschini,
Maria Ausilia Teriaca,
Luca Dominici,
Ciro Franzese,
Marta Scorsetti
Publication year - 2021
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s294116
Subject(s) - sabr volatility model , ablative case , medicine , radiosurgery , stereotactic radiation therapy , population , radiation therapy , medical physics , oncology , radiology , volatility (finance) , stochastic volatility , financial economics , economics , environmental health
Oligometastatic patients are a heterogeneous and yet not well-defined population. The actual definition identifies as oligometastatic, patients with 1-5 metastases in 1-3 different organs. However, only a proportion of these patients are "true" oligometastatic and therefore derive some kinds of benefit from local ablative approaches like stereotactic ablative radiation therapy (SABR). Since SABR is an easily accessible, effective and well-tolerated treatment, it is widely employed in the oligometastatic scenarios, without a particular focus on selection criteria. However, it should be crucial to identify predictive and prognostic features that could be clinically implemented. Therefore, we conducted this narrative review of the available literature to summarize all clinical, radiomic, genetic and epigenetic features found to be predictive of overall survival, progression-free survival or local control of oligometastatic patients treated with SABR.